

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/517,518
Applicant : Stefan SPERL
Filed : July 1, 2005
TC/A.U. : 1621
Examiner : S. KUMAR

Docket No. : 2923-671
Customer No. : 06449
Confirmation No. : 1246

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450


SECOND DECLARATION UNDER 37 C.F.R. '1.132

I, Stefan Sperl, declare as follows:


1. I am the inventor of the above-identified application.
2. My educational background is as follows: Chemist, Ph.D. I am currently employed as a Project Manager Preclinics at Nabriwa Therapeutics GmbH, Vienna, Austria.
3. The following experiments were conducted by me or under my supervision and control.
4. The in-vitro inhibition of urokinase, plasmin and thrombin by three compounds were determined as set forth in Examples 3 and 4 of the present application. The KI data are presented below.

Compound	uPA [μ M]	Plasmin [μ M]	Thrombin [μ M]
WX-682	0.39	5.16	9.4
WX-684	0.93	4.04	25.2


WX-UK1	0.65	1.46	0.5
Pefabloc® uPA (Pentapharm Product Catalog 1998)	0.41	1.0	0.67



WX-682



WX-684



WX-UK1

I note that Compound WX-682 and WX-684 are the subject of the present application, and that Compound WX-UK1 corresponds to the Pefabloc® uPA compound from the Pentapharm Product Catalog 1998. Those data show that the compounds of the present invention have a much higher selectivity for urokinase compared to thrombin and plasmin than does the Pentapharm compound. The high selectivity of the compounds of the present invention is surprising and unexpected.

5. I further note that while the data I generated for the Pentapharm product are not identical to the data for that compound presented in the Pentapharm Product Catalog 1998, it is not uncommon to see such variability in multiple experiments. However, even with that variability, the lack of selectivity for urokinase compared to thrombin and plasmin is clear in both sets of data.

6. All statements made herein of my own knowledge are true, and all statements made on information and belief are believed to be true. All statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Stefan Sperl
Dr. Stefan Sperl

13. 11. 2007
Date